Physicians at the University of Illinois Hospital & Health Sciences System have cured 12 adult patients of sickle cell disease using a unique procedure for stem cell transplantation from healthy, tissue-matched siblings.
The transplants were the first to be performed outside of the National Institutes of Health campus in Maryland, where the procedure was developed. Physicians there have treated 30 patients, with an 87 percent success rate. The results of the phase I/II clinical trial at UI Health, in which 92 percent of treated patients were cured, are published online in the journal Biology of Blood & Marrow Transplantation.
The new technique eliminates the need for chemotherapy to prepare the patient to receive the transplanted cells and offers the prospect of cure for tens of thousands of adults suffering from sickle cell disease.
About 90 percent of the approximately 450 patients who have received stem cell transplants for sickle cell disease have been children. Chemotherapy has been considered too risky for adult patients, who are often more weakened than children by the disease.
“Adults with sickle cell disease are now living on average until about age 50 with blood transfusions and drugs to help with pain crises, but their quality of life can be very low,” says Dr. Damiano Rondelli, chief of hematology/oncology and director of the blood and marrow transplant program at UI Health, and corresponding author on the paper.
“Now, with this chemotherapy-free transplant, we are curing adults with sickle cell disease, and we see that their quality of life improves vastly within just one month of the transplant,” said Rondelli, who is also the Michael Reese Professor of Hematology in the UIC College of Medicine. “They are able to go back to school, go back to work, and can experience life without pain.”
Sickle cell disease is inherited. It primarily affects people of African descent, including about one in every 500 African Americans born in the U.S. The defect causes the oxygen-carrying red blood cells to be crescent shaped, like a sickle. The misshapen cells deliver less oxygen to the body’s tissues, causing severe pain and eventually stroke or organ damage.
Doctors have known for some time that bone marrow transplantation from a healthy donor can cure sickle cell disease. But few adults were transplanted because high-dose chemotherapy was needed to kill off the patients’ own blood-forming cells — and their entire immune system, to prevent rejection of the transplanted cells, leaving patients open to infection.
In the new procedure, patients receive immunosuppressive drugs just before the transplant, along with a very low dose of total body irradiation — a treatment much less harsh and with fewer potentially serious side effects than chemotherapy.
Next, donor cells from a healthy and tissue-matched sibling are transfused into the patient. Stem cells from the donor produce healthy new blood cells in the patient, eventually in sufficient quantity to eliminate symptoms. In many cases, sickle cells can no longer be detected. Patients must continue to take immunosuppressant drugs for at least a year.
In the reported trial, the researchers transplanted 13 patients, 17 to 40 years of age, with a stem cell preparation from the blood of a tissue-matched sibling. Healthy sibling donor-candidates and patients were tested for human leukocyte antigen, a set of markers found on cells in the body. Ten of these HLA markers must match between the donor and the recipient for the transplant to have the best chance of evading rejection.
In a further advance of the NIH procedure, physicians at UI Health successfully transplanted two patients with cells from siblings who matched for HLA but had a different blood type.
In all 13 patients, the transplanted cells successfully took up residence in the marrow and produced healthy red blood cells. One patient who failed to follow the post-transplant therapy regimen reverted to the original sickle cell condition.
None of the patients experienced graft-versus-host disease, a condition where immune cells originating from the donor attack the recipient’s body.
One year after transplantation, the 12 successfully transplanted patients had normal hemoglobin concentrations in their blood and better cardiopulmonary function. They reported less pain and improved health and vitality.
Four of the patients were able to stop post-transplantation immunotherapy without transplant rejection or other complications.
The Latest on: Sickle cell disease
via Google News
The Latest on: Sickle cell disease
- Santonio Holmes Back In Pittsburgh, Raising Awareness About Sickle Cell Diseaseon October 9, 2020 at 1:48 pm
Former Pittsburgh Steelers wide receiver Santonio Holmes is back in Pittsburgh. He’s hosting the fourth annual Strikes Against Sickle Cell Bowling event this weekend. While the event went virtual this ...
- Sickle cell disease is challenging but not insurmountable for son of Lakeland commissioneron October 6, 2020 at 2:12 pm
Lakeland resident Christian Walker, the son of Commissioner Philip Walker, has battled sickle cell disease for 20 years. Christian now is on a drug called hydroxyurea to reduce his need for ...
- Options for treating sickle cell disease expanded last fallon October 6, 2020 at 1:43 pm
Two new therapy options won Food and Drug Administration approval within 10 days of each other in November 2019, blooms of hope in what has been a relatively unchanging landscape. Adakveo, approved ...
- $7.1M grant to review opioid alternatives to treating sickle cell disease painon October 6, 2020 at 12:01 pm
Researchers at the University of Illinois Chicago will lead a $7.1 million, five-year national study to determine the effectiveness of acupuncture and guided relaxation for people with chronic pain ...
- FDA Grants GlycoMimetics Rare Pediatric Disease Designation for Rivipansel for Treatment of Sickle Cell Diseaseon October 5, 2020 at 1:34 pm
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that the U.S. Food and Drug Administration (FDA) has granted the Company a Rare Pediatric Disease designation for rivipansel for the treatment of ...
- Sickle cell disease didn't stop Lakesha Dickerson — it inspired her to become a nurseon October 5, 2020 at 6:00 am
Growing up with sickle cell disease, Lakesha Thomas Dickerson essentially spent her childhood in doctors’ offices and hospitals.
- The FDA Should Approve New Treatments for Sickle Cell Patientson October 2, 2020 at 6:08 am
It’s been decades since the FDA has approved new treatments for the benefit of patients with sickle cell disease.”Sonya L. Banks, president of the Sickle Cell Disease Association of America ...
- Approximately 40 percent of babies born with sickle cell disease in Texas are in Houstonon October 1, 2020 at 3:07 pm
There are about 180 babies born with sickle cell disease in Texas each year, and approximately 40 percent (70 children) are born in Houston. The Houston Health Department said in a press release that ...
- Aflac Contributes $1.5 Million to Sickle Cell Disease Program at the Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlantaon September 30, 2020 at 1:30 pm
September is National Sickle Cell Awareness Month, and Aflac, a leader in supplemental insurance sales at U.S. worksites, today announced ...
- Life as a sickle cell warrior: How advocates are changing the face of the diseaseon September 30, 2020 at 12:29 pm
sickle cell advocate Shamonica Wiggins shares with theGrio. Sickle cell disease (SCD) is a group of red blood cell disorders occurring when a child inherits the sickle cell gene from both parents ...
via Bing News